French Eye Care Lab Horus Pharma Acquires Stake in Inocare Pharm

Horus Pharma, the leading independent French ophthalmology laboratory, founded in 2003, announces that it is taking a significant stake in the Romanian ophthalmology company Inocare Pharm, based in Bucharest.
“Romania is an ideal regional base to meet the demand for high-quality ophthalmic solutions and services in the Balkans and the Commonwealth of Independent States,” the French company said.
Founded ten years ago by a mixed team of Romanian-Italian entrepreneurs, with solid experience in the pharmaceutical and especially ophthalmic fields, Inocare Pharm was taken over by Dr. Carmen Tudose as CEO in 2018. She forged a solid reputation in the Romanian ophthalmological world through the successful launch of companies such as Biosooft Romania, a subsidiary of SOOFT Italia (currently Fidia) and Santen Japan.

Inocare Pharm specializes in the distribution of medical devices, dietary supplements promoting eye health, and diagnostic tools, collaborating with international manufacturers such as OFFHealth (Italy), Optima (Germany), and Tear Lab (United States). With its team of ten employees, the company generates revenues of 3 million euros, marking a 25% increase from the previous year.

This acquisition represents an exceptional opportunity for Inocare Pharm. By joining forces with Horus Pharma, a leading European company in ophthalmology, Inocare will expand its product portfolio and introduce new medications, strengthening its position in the Romanian market and extending into the Balkans and former CIS territories. Meanwhile, Horus Pharma gains access to rapidly growing Eastern European markets and will contribute to meeting the needs of ophthalmologists and patients,” stated the French company.

Nicolas Claret, Horus Pharma’s International Director, commented: “This partnership is a crucial growth driver that will help strengthen our international presence. By leveraging our pharmaceutical expertise, Inocare will expand its market share in Romania and increase its influence in the Balkans and Central Asia. Our decision to partner with an established business like Inocare Pharm provides us with a committed, high-performing management team and access to experienced professionals, capable of meeting the needs of patients and healthcare providers efficiently. We are excited to embark on this new venture with Carmen Tudose, and we have full confidence in her ability to lead this joint project to success.”

Dr. Carmen Tudose, CEO and founder of Inocare, added, “We are delighted to welcome Horus Pharma as a shareholder. Over the past 20 years, Horus Pharma has established itself as a key player in the European ophthalmology market by introducing innovative products, and we are eager to benefit from its substantial expertise. This strategic collaboration will expand our range and strengthen our position in the local market, while enabling us to expand into the Balkans and other regions where the demand for high-quality ophthalmic solutions is rapidly growing.”

Bucharesteye care labFrenchHorus PharmaInocare Pharmophthalmology laboratorystake
Comments (0)
Add Comment